How India Exports Tamoxifen to the World

Tamoxifen has been a cornerstone in breast cancer treatment in the United States, with numerous Abbreviated New Drug Applications (ANDAs) approved by the FDA. For instance, Teva Pharmaceutical Industries Ltd. received final FDA approval for Tamoxifen Citrate 10 mg tablets on June 1, 2000. The regulatory pathway for Tamoxifen involves demonstrating bioequivalence to the reference listed drug, ensuring safety and efficacy. Given the substantial number of Indian exporters (220) supplying Tamoxifen to the U.S., compliance with FDA regulations, including Good Manufacturing Practices (GMP) and periodic inspections, is imperative to maintain market access.

In the European Union, Tamoxifen is subject to stringent regulatory oversight. The European Medicines Agency (EMA) conducts periodic safety update report single assessments (PSUSAs) for Tamoxifen, with the most recent procedure (PSUSA/00002846/202504) resulting in a variation to the marketing authorization in March 2026. (ema.europa.eu) Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) oversees Tamoxifen's market authorization. For example, in June 2025, Wockhardt UK Ltd. recalled a batch of Tamoxifen 20 mg film-coated tablets due to a dissolution failure identified during stability testing. (gov.uk) Compliance with EU GMP requirements is mandatory for manufacturers exporting to these markets, ensuring product quality and patient safety.

Tamoxifen is included in the 24th WHO Model List of Essential Medicines, published in September 2025, underscoring its critical role in global health. (who.int) This inclusion signifies its importance in treating priority health conditions worldwide. Manufacturers must adhere to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure product quality and facilitate global distribution.

In India, Tamoxifen is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for Tamoxifen exports, ensuring compliance with national regulations and monitoring of pharmaceutical exports.

The primary patents for Tamoxifen have expired, leading to a competitive generic market. However, companies continue to develop novel formulations and derivatives. For instance, in April 2025, Atossa Therapeutics announced the issuance of U.S. Patent No. 12,281,056, covering various formulations of its (Z)-endoxifen portfolio, a potent Selective Estrogen Receptor Modulator (SERM). This indicates ongoing innovation in the field, potentially impacting the competitive landscape.

In June 2025, the MHRA issued a Class 3 medicines recall for Tamoxifen 20 mg film-coated tablets produced by Wockhardt UK Ltd., following the identification of a dissolution failure during stability testing. (gov.uk) This underscores the importance of stringent quality control measures for manufacturers.

In March 2026, the EMA concluded a periodic safety update report single assessment (PSUSA/00002846/202504) for Tamoxifen, resulting in a variation to the marketing authorization. (ema.europa.eu) This highlights the continuous regulatory scrutiny to ensure the safety and efficacy of Tamoxifen in the European market.

These developments emphasize the dynamic regulatory environment surrounding Tamoxifen, necessitating vigilant compliance and quality assurance from manufacturers and exporters.

India's pharmaceutical industry, including the production of Tamoxifen, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these essential components are sourced from China, highlighting a significant dependency. This reliance poses a substantial risk, as any disruption in the supply chain from China can directly impact the availability and production of Tamoxifen in India.

Recent geopolitical tensions have exacerbated this vulnerability. In February 2026, escalating conflicts in the Middle East led to the closure of the Strait of Hormuz, a critical maritime route for global trade. This disruption has caused significant delays and increased costs in shipping, affecting the timely import of APIs and KSMs into India. Consequently, the production schedules for Tamoxifen have been adversely affected, leading to potential shortages in both domestic and international markets.

The export market for Tamoxifen from India is highly concentrated, with the top five exporters accounting for 87.8% of the total export value. EUGIA PHARMA SPECIALITIES LIMITED leads with a 45.3% share, followed by PRATAP ORGANICS PRIVATE LIMITED (19.1%), GRANULES INDIA LIMITED (12.7%), BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED (5.6%), and KHANDELWAL LABORATORIES PRIVATE LIMITED (5.0%). This high concentration indicates a significant single-source risk, as any operational or financial issues within these key companies could disrupt the global supply of Tamoxifen.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of APIs and reduce dependency on imports. However, as of March 2026, the effectiveness of this scheme in diversifying the supplier base for Tamoxifen remains to be fully realized. Continued monitoring and support are essential to ensure the scheme's success in enhancing supply chain resilience.

The closure of the Strait of Hormuz in February 2026, due to military conflicts involving Iran, the United States, and Israel, has severely disrupted global shipping routes. This strait is a vital passage for approximately 20% of the world's daily oil supply and significant volumes of liquefied natural gas. The blockade has led to increased shipping costs, delays, and rerouting of vessels, impacting the timely delivery of pharmaceutical products, including Tamoxifen.

Additionally, tensions in the Red Sea and the Strait of Hormuz have prompted major shipping companies to suspend operations in these regions, further complicating logistics. The U.S. and its allies have considered forming coalitions to reopen these critical waterways, but as of March 2026, these efforts have not fully restored normal shipping activities.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers for APIs and KSMs, both domestically and from other countries, to reduce dependency on a single source.

• Enhance Domestic Production: Strengthen initiatives like the PLI scheme to boost local manufacturing capabilities for APIs and KSMs, ensuring a more self-reliant supply chain.

• Develop Alternative Shipping Routes: Invest in and establish alternative logistics and shipping routes to mitigate the impact of geopolitical disruptions in critical maritime passages.

• Strengthen Supplier Relationships: Foster strong partnerships with multiple suppliers to ensure flexibility and resilience in the supply chain.

• Implement Robust Risk Management Strategies: Develop comprehensive risk assessment and management plans to proactively address potential supply chain disruptions.

RISK_LEVEL: HIGH